Oncolytic Sendai virus-induced tumor-specific immunoresponses suppress "simulated metastasis" of squamous cell carcinoma in an immunocompetent mouse model.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30620422.
- Also identified by DOI 10.1002/hed.25642.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The objectives of this study were to demonstrate anti-metastatic effect of BioKnife, uPA activity-dependent oncolytic Sendai virus, after BioKnife treatment for primary tumor, and analyze its mechanisms in a simulated metastasis mouse model of head and neck squamous cell carcinoma (HNSCC). We established a simulated metastasis mouse model using a murine HNSCC cell line "SCCVII." We assessed a tumor size and an induction of tumor-specific immunoresponses using cytotoxic T-lymphocyte (CTL) assay, flow cytometry (FCM) in spleen and immunohistochemistry (IHC) in secondary tumor. Secondary tumors were significantly smaller in BioKnife-treated group. CTL activities were significantly improved in BioKnife group. FCM revealed that induction of dendritic cells and CD4<sup>+</sup> /CD8<sup>+</sup> lymphocytes was significantly higher in BioKnife group. IHC showed that CD8<sup>+</sup> lymphocytes invaded secondary tumor. Tumor-specific immunoresponses induced by BioKnife has great potential to be a novel, safe, and less invasive option for control and prevention of metastasis.
Medical subject headings
- Carcinoma, Squamous Cell
- Head and Neck Neoplasms
- Oncolytic Virotherapy
- Oncolytic Viruses
- Sendai virus